StockNews.com Upgrades Edwards Lifesciences (NYSE:EW) to “Buy”

StockNews.com upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a report published on Monday.

Several other analysts have also issued reports on EW. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an outperform rating in a research report on Monday, April 15th. Mizuho lifted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a buy rating in a research note on Thursday, April 11th. Bank of America upgraded Edwards Lifesciences from a neutral rating to a buy rating in a research report on Thursday, March 7th. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the company a hold rating in a research report on Friday. Finally, Piper Sandler boosted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a research note on Friday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $92.71.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $85.95 on Monday. The business has a fifty day moving average price of $90.27 and a two-hundred day moving average price of $79.06. The stock has a market capitalization of $51.74 billion, a PE ratio of 37.05, a P/E/G ratio of 4.28 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, equities analysts predict that Edwards Lifesciences will post 2.76 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of EW. Mayflower Financial Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $531,000. OFI Invest Asset Management boosted its stake in shares of Edwards Lifesciences by 43.5% during the 1st quarter. OFI Invest Asset Management now owns 13,886 shares of the medical research company’s stock worth $1,229,000 after acquiring an additional 4,208 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Edwards Lifesciences by 4.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock valued at $31,603,000 after acquiring an additional 14,087 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of Edwards Lifesciences by 30.9% in the first quarter. Commonwealth Equity Services LLC now owns 181,263 shares of the medical research company’s stock worth $17,322,000 after purchasing an additional 42,744 shares in the last quarter. Finally, FAS Wealth Partners Inc. raised its position in shares of Edwards Lifesciences by 3.3% during the 1st quarter. FAS Wealth Partners Inc. now owns 25,050 shares of the medical research company’s stock valued at $2,394,000 after purchasing an additional 806 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.